Home Cart Sign in  
Chemical Structure| 78628-80-5 Chemical Structure| 78628-80-5

Structure of Terbinafine HCl
CAS No.: 78628-80-5

Chemical Structure| 78628-80-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Terbinafine HCl is a naphthalene-derived allylamine antifungal, working by inhibiting squalene monooxygenase thereby blocking the biosynthesis of ergosterol, which is an essential component of fungal cell membranes.

Synonyms: Terbinafine (hydrochloride); TDT 067 hydrochloride; Terbinafine hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Terbinafine HCl

CAS No. :78628-80-5
Formula : C21H26ClN
M.W : 327.89
SMILES Code : CN(CC1=C2C(C=CC=C2)=CC=C1)C/C=C/C#CC(C)(C)C.[H]Cl
Synonyms :
Terbinafine (hydrochloride); TDT 067 hydrochloride; Terbinafine hydrochloride
MDL No. :MFCD00145430
InChI Key :BWMISRWJRUSYEX-SZKNIZGXSA-N
Pubchem ID :5282481

Safety of Terbinafine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Madurella pseudomycetomatis 2 μg/ml To test the in vitro antifungal activity of terbinafine against Madurella pseudomycetomatis, showing moderate susceptibility. nov., a novel opportunistic fungus possibly causing black-grain mycetoma. J Clin Microbiol.
C4-2 50 µM 48 hours To evaluate the effect of Terbinafine on cholesterol synthesis. Results showed that Terbinafine significantly inhibited cholesterol synthesis. Nat Commun. 2021 Aug 20;12(1):5066.
LNCaP 50 µM 48 hours To evaluate the inhibitory effect of Terbinafine on SQLE activity and its impact on cholesterol synthesis. Results showed that Terbinafine significantly inhibited cholesterol synthesis. Nat Commun. 2021 Aug 20;12(1):5066.
DLD1 cells 1–50 μM To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of DLD1 cells. Mol Ther. 2022 Oct 5;30(10):3284-3299.
LoVo cells 1–50 μM To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of LoVo cells. Mol Ther. 2022 Oct 5;30(10):3284-3299.
HT29 cells 1–50 μM To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HT29 cells. Mol Ther. 2022 Oct 5;30(10):3284-3299.
HCT116 cells 1–50 μM To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HCT116 cells. Mol Ther. 2022 Oct 5;30(10):3284-3299.
HCT116 cells 30μM 72 hours Terbinafine suppressed cholesterol accumulation in both p53+/+ and p53-/- HCT116 cells EMBO Rep. 2021 Oct 5;22(10):e52537.
HepG2 cells 30μM 72 hours Terbinafine suppressed cholesterol accumulation in both p53+/+ and p53-/- HepG2 cells, with a more profound effect on p53-/- cells EMBO Rep. 2021 Oct 5;22(10):e52537.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Mouse ear tissue Topical application 1% (w/w) 30 minutes Tracking drug delivery pathways of terbinafine in mouse ear tissue Nat Methods. 2014 Apr;11(4):410-2.
Mice Orthotopic prostate cancer xenograft model Intraperitoneal injection 50 mg/kg Every 48 hours for six weeks To evaluate the inhibitory effect of Terbinafine on tumor growth. Results showed that Terbinafine significantly inhibited tumor growth and reduced serum PSA levels. Nat Commun. 2021 Aug 20;12(1):5066.
Mice AOM/DSS-induced CRC model, orthotopic CRC mouse models, and APCmin/+ mouse models Intraperitoneal injection 20 mg/kg (AOM/DSS model), 50 mg/kg (orthotopic CRC model) To evaluate the antitumor effect of terbinafine in CRC mouse models, results showed that terbinafine significantly reduced tumor numbers and sizes and prolonged survival time. Mol Ther. 2022 Oct 5;30(10):3284-3299.
Mice MASH-HCC model Oral gavage 80 mg/kg Once daily for 7 weeks To evaluate the effect of Terbinafine on tumor growth and immune microenvironment in MASH-HCC model, results showed that Terbinafine significantly suppressed tumor growth, increased tumor-infiltrating functional CD8+ T cells, and reduced Arg-1+ MDSCs Gut. 2024 Nov 11;73(12):2023-2036
Nude mice HT29 cell subcutaneous xenograft model Oral 80 mg/kg Daily for 4 weeks Terbinafine alone suppressed tumor growth by ~50%, and showed synergistic effects when combined with 5-FU or oxaliplatin Gut. 2022 Nov;71(11):2253-2265
Nude mice RKO xenograft model Subcutaneous injection 100 mg Terbinafine: once daily for 10 days; 5-FU: twice weekly for 2 weeks To evaluate the enhancing effect of terbinafine on 5-FU treatment, results showed that terbinafine significantly improved the antitumoral efficacy of 5-FU. Cell Commun Signal. 2024 May 18;22(1):278.
Mice High-fat diet-induced nonalcoholic fatty liver disease (NAFLD) model Oral 80mg/kg Once daily for 8 weeks Terbinafine inhibited high-fat diet-induced fat liver formation and cholesterol accumulation in p53-/- mice EMBO Rep. 2021 Oct 5;22(10):e52537.
Mice KCC2 knockdown mouse model Intracerebroventricular injection 1 mM 30 minutes before and 4 hours after the first injection, and another injection 30 minutes before testing the next day Reduced neuronal excitability and occluded memory impairment upon KCC2 knockdown Neuropsychopharmacology. 2023 Jun;48(7):1067-1077

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00002394 Candidiasis, Oral|HIV Infectio... More >>ns Less << COMPLETED - Therafirst Med Ctr, Fort Laude... More >>rdale, Florida, 33308, United States|Associates in Research, Fort Myers, Florida, 33901, United States|Clireco Inc, Tamarac, Florida, 33321, United States|Infectious Diseases Research Inc, Tampa, Florida, 33614, United States|Northwestern Univ / Division of Infectious Disease, Chicago, Illinois, 60611, United States|Saint Michaels Med Ctr / Infectious Disease Resch Dpt, Newark, New Jersey, 071029880, United States|St Vincents Hosp / Clinical Research Program, New York, New York, 10011, United States|Univ of Texas Med Branch, Galveston, Texas, 77555, United States|Hampton Roads Med Specialists, Hampton, Virginia, 23666, United States Less <<
NCT01484145 Onychomycosis PHASE2 COMPLETED 2025-04-12 Cetero Research, San Antonio, ... More >>Texas, 78229, United States Less <<
NCT00117754 Tinea Capitis PHASE3 COMPLETED 2025-04-06 Novartis Pharmaceuticals, East... More >> Hanover, New Jersey, 07936, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.05mL

0.61mL

0.30mL

15.25mL

3.05mL

1.52mL

30.50mL

6.10mL

3.05mL

References

 

Historical Records

Categories